Phaseline

Companies › Newsoara Biopharma

Newsoara Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HY6725–Phase 1HealthyMar 2027
HY8931–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07281703HY8931Phase 1HealthyOtherSep 2026
NCT07262281HY6725Phase 1HealthyOtherMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.